Copyright © 2015 by the American Osteopathic Association. From: C-Reactive Protein: A New Risk Assessment Tool for Cardiovascular Disease J Am Osteopath Assoc. 2005;105(9):409-416. doi:10.7556/jaoa.2005.105.9.409 Figure Legend: High-sensitivity C-reactive protein adds prognostic information on vascular risk at all levels of the Framingham Risk Score (left) and all levels of low-density lipoprotein (LDL) cholesterol (right). (Adapted from Ridker PM, for the JUPITER Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial [review].Circulation. 2003;108[19]:2292-2297.) Date of download: 3/9/2018 Copyright © 2015 by the American Osteopathic Association. All rights reserved.